Elbit Imaging Ltd. (EMITF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören Elbit Imaging Ltd. (EMITF), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 42/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 18 Mar 2026Elbit Imaging Ltd. (EMITF) Sağlık ve Boru Hattı Genel Bakışı
Elbit Imaging Ltd. operates in the healthcare sector, developing and marketing non-invasive therapeutic medical systems and stem cell-based products. The company also has real estate interests in India, reflecting a diversified business model within a small-cap framework and OTC market presence.
Yatırım Tezi
Elbit Imaging Ltd. presents a speculative investment opportunity due to its presence in the medical device and stem cell therapy sectors, coupled with its real estate ventures in India. With a market capitalization of $0.02 billion and a negative P/E ratio of -4.98, the company's financial performance indicates challenges in achieving profitability. Growth catalysts may include advancements in its therapeutic medical systems and successful real estate sales in India. However, the company's OTC listing and limited financial disclosure pose significant risks. The company's beta of 0.24 suggests low volatility relative to the market. Investors should carefully consider the risks associated with OTC-listed companies and the uncertainties surrounding Elbit Imaging's diverse business activities before investing.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.02 billion indicates a micro-cap company with limited resources.
- Negative P/E ratio of -4.98 reflects current unprofitability.
- Beta of 0.24 suggests lower volatility compared to the overall market.
- No dividend yield, indicating that the company is not returning profits to shareholders.
- The company operates in both the healthcare (medical devices and stem cell therapies) and real estate sectors, diversifying its business interests.
Rakipler & Benzerleri
Güçlü Yönler
- Proprietary medical technologies.
- Diversified business interests (healthcare and real estate).
- Global distribution network.
- Expertise in stem cell-based therapies.
Zayıflıklar
- Small market capitalization.
- Negative P/E ratio indicating unprofitability.
- OTC market listing.
- Limited financial disclosure.
Katalizörler
- Upcoming: Potential regulatory approvals for new medical devices in key markets.
- Ongoing: Expansion of distribution network for therapeutic medical systems.
- Ongoing: Progress in real estate development projects in India.
- Ongoing: Advancements in stem cell therapy research and development.
Riskler
- Potential: Competition from larger medical device companies.
- Potential: Regulatory hurdles for medical devices and stem cell therapies.
- Ongoing: Economic and political risks in India affecting real estate ventures.
- Ongoing: Limited access to capital due to small market capitalization.
- Ongoing: OTC market listing and limited financial disclosure.
Büyüme Fırsatları
- Expansion of Therapeutic Medical Systems: The market for non-invasive therapeutic medical systems is growing as patients seek less invasive treatment options. Elbit Imaging can capitalize on this trend by expanding its product offerings and distribution network. The global market for medical devices is projected to reach $600 billion by 2028, offering a substantial opportunity for growth. Timeline: Ongoing.
- Advancements in Stem Cell Therapies: The stem cell therapy market is experiencing rapid growth due to its potential to treat a wide range of diseases. Elbit Imaging can invest in research and development to create new stem cell-based therapies and expand its market share. The global stem cell therapy market is expected to reach $17 billion by 2025. Timeline: Ongoing.
- Real Estate Development in India: India's real estate market is experiencing growth, driven by urbanization and increasing disposable incomes. Elbit Imaging can leverage its real estate holdings in India to generate revenue through property sales and development projects. The Indian real estate market is projected to reach $1 trillion by 2030. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Elbit Imaging can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborating with other companies in the medical device and stem cell therapy sectors can accelerate innovation and market penetration. Timeline: Ongoing.
- Regulatory Approvals and Market Access: Obtaining regulatory approvals for its medical devices and stem cell therapies in key markets is crucial for Elbit Imaging's growth. Successfully navigating the regulatory landscape and securing market access in regions such as the United States, Europe, and Asia can significantly boost revenue and profitability. Timeline: Ongoing.
Fırsatlar
- Expansion of non-invasive treatment market.
- Growth in stem cell therapy market.
- Real estate development opportunities in India.
- Strategic partnerships and acquisitions.
Tehditler
- Competition from larger medical device companies.
- Regulatory hurdles for medical devices and stem cell therapies.
- Economic and political risks in India.
- Limited access to capital.
Rekabet Avantajları
- Proprietary medical technologies for non-invasive treatments.
- Expertise in stem cell-based medical products.
- Established distribution network in multiple regions.
- Real estate holdings in India.
EMITF Hakkında
Elbit Imaging Ltd., established in 1996 and headquartered in Petach Tikva, Israel, operates primarily in the healthcare sector, focusing on the development, production, and marketing of therapeutic medical systems. These systems are designed for non-invasive treatments using ultrasound beam and magnetic resonance imaging technologies. The company's medical systems are distributed across North and South America, Europe, Asia, and Oceania. In addition to its medical systems, Elbit Imaging offers medical products based on stem cells derived from umbilical cord blood, intended for bone marrow transplantation in patients with leukemia, lymphoma, non-malignant blood diseases, and metabolic genetic diseases. Beyond its healthcare activities, Elbit Imaging is also involved in real estate, specifically the sale of plots and villas in India, diversifying its revenue streams and business interests. The company's small size and OTC market listing reflect its position as a niche player with a diverse portfolio.
Ne Yaparlar
- Develops therapeutic medical systems for non-invasive treatments.
- Produces and markets medical systems using ultrasound beam and magnetic resonance imaging.
- Offers medical products based on stem cells derived from umbilical cord blood.
- Focuses on treatments for leukemia, lymphoma, and other blood diseases.
- Engages in the sale of plots and villas in India.
- Distributes medical systems in North and South America, Europe, Asia, and Oceania.
İş Modeli
- Generates revenue from the sale of therapeutic medical systems.
- Earns income from the sale of stem cell-based medical products.
- Derives revenue from real estate sales in India.
Sektör Bağlamı
Elbit Imaging Ltd. operates within the medical device and stem cell therapy industries, which are characterized by rapid technological advancements and stringent regulatory requirements. The company also has exposure to the Indian real estate market. The medical device industry is projected to grow, driven by an aging population and increasing demand for non-invasive treatments. The stem cell therapy market is also expected to expand, fueled by advancements in regenerative medicine. However, Elbit Imaging faces competition from larger, more established players such as ASAPF, BTCY, GTHP, IPDQF, and ISCNF. The company's success depends on its ability to innovate and navigate the regulatory landscape effectively.
Kilit Müşteriler
- Hospitals and medical centers.
- Oncology clinics.
- Patients requiring non-invasive treatments.
- Individuals seeking stem cell-based therapies.
- Real estate buyers in India.
Finansallar
Grafik & Bilgi
Elbit Imaging Ltd. (EMITF) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 Mar 2020
-
Stocks That Hit 52-Week Lows On Friday
· 16 Ağu 2019
-
Stocks Which Set New 52-Week Low Yesterday, October 31st
· 1 Kas 2018
-
Stocks Which Set New 52-Week Low Friday, October 26th
· 29 Eki 2018
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
EMITF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
EMITF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, EMITF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Eran Mazor
CEO
Eran Mazor serves as the CEO of Elbit Imaging Ltd., overseeing the company's operations in the medical device and real estate sectors. His background includes experience in managing small teams and navigating the challenges of a micro-cap company. He is responsible for the strategic direction of the company, focusing on growth opportunities in the healthcare and real estate markets. He manages a team of 3 employees.
Sicil: Under Eran Mazor's leadership, Elbit Imaging has continued to develop and market its therapeutic medical systems and stem cell-based products. He has also overseen the company's real estate activities in India. His tenure has focused on maintaining the company's operations and exploring opportunities for growth within its niche markets.
EMITF OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or have chosen not to comply with the reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, making it difficult to assess their financial health and operational performance. Unlike NYSE or NASDAQ-listed companies, OTC Other firms face fewer regulations, leading to increased risks for investors due to potential lack of transparency and liquidity.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure due to OTC Other listing.
- Low liquidity and wide bid-ask spreads.
- Potential for price manipulation and fraud.
- Higher risk of delisting or trading suspension.
- Lack of regulatory oversight compared to NYSE or NASDAQ.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags, such as lawsuits or regulatory actions.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 1996.
- Focus on medical device and stem cell therapy sectors.
- Global distribution network for medical systems.
- Involvement in real estate activities in India.
Elbit Imaging Ltd. Hissesi: Cevaplanan Temel Sorular
EMITF için değerlendirilmesi gereken temel faktörler nelerdir?
Elbit Imaging Ltd. (EMITF) şu anda yapay zeka skoru 42/100, düşük puanı gösteriyor. Temel güçlü yan: Proprietary medical technologies.. İzlenmesi gereken birincil risk: Potential: Competition from larger medical device companies.. Bu bir finansal tavsiye değildir.
EMITF MoonshotScore'u nedir?
EMITF şu anda MoonshotScore'da 42/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
EMITF verileri ne sıklıkla güncellenir?
EMITF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler EMITF hakkında ne diyor?
EMITF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
EMITF'a yatırım yapmanın riskleri nelerdir?
EMITF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from larger medical device companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
EMITF'ın P/E oranı nedir?
EMITF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için EMITF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
EMITF aşırı değerli mi, yoksa düşük değerli mi?
Elbit Imaging Ltd. (EMITF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
EMITF'ın temettü verimi nedir?
Elbit Imaging Ltd. (EMITF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Information is based on available company data and may be limited due to the company's OTC listing.
- AI analysis pending for EMITF.